Medical Imaging in Massachusetts

QMENTA is a cloud-based medical imaging AI platform founded in 2013 that specializes in neuroimaging data management, processing, visualization, and analysis for clinical trials, research, and diagnostic support. The platform serves biopharmaceutical companies, CROs, medical device manufacturers, academic institutions, and diagnostic centers. QMENTA's integrated infrastructure includes Smart Uploader with HIPAA-compliant PHI de-identification, secure cloud PACS connectivity with automated workflows, over 50 AI-powered imaging biomarkers, Central Review capabilities for remote collaboration, and an Imaging Management System with EDC and query management tools. The company has processed 13M+ imaging scans for 1M+ study participants across 250+ connected sites and completed 1M+ AI imaging analyses. Solutions address neurological diseases, oncology, and rare disease diagnostics with demonstrated cost reductions (50%) and reading time improvements (75%).

R.B. Enterprise, Inc. is a medical service company with over 25 years of experience specializing in maintenance, repair, and support for diagnostic imaging equipment. The company provides comprehensive service offerings including maintenance and service contracts, equipment refurbishing and upgrades, installations and de-installations, and supply and leasing solutions. Core competencies span MRI, CT, ultrasound, X-ray, C-arm fluoroscopy, and gamma camera systems, as well as imaging peripherals. R.B. Enterprise is known for specialized ultrasound probe repair capabilities, same-day response times, employment of professional licensed engineers, in-house latest technology infrastructure, and use of only original OEM parts. The company serves healthcare facilities requiring imaging equipment support and serves as a vendor for both routine maintenance contracts and emergency repair services.

Coghlin Companies, Inc. is a fourth-generation contract manufacturing and engineering services company (founded 1885) specializing in the design, engineering, and precision manufacturing of complex capital equipment and medical devices. Based in Westborough, Massachusetts, with ~480 employees and $159.9M annual revenue, the company serves medical life sciences, semiconductor, robotics, and industrial sectors. Core capabilities include product engineering, design for manufacturability (DFM), prototyping, printed circuit board assembly, total system integration, and global supply chain fulfillment. Notable achievements include manufacturing 10,000 ventilators during COVID-19. Coghlin operates both industrial (Columbia Tech) and medical (Cogmedix) divisions, providing end-to-end commercialization services from concept through scalable manufacturing and aftermarket support.

Oncovision is a Spanish-based medical imaging company specializing in innovative diagnostic and therapeutic imaging devices for oncology, radiology, surgery, and nuclear medicine. The company develops molecular imaging solutions focused on early cancer detection and treatment planning. Primary product lines include Mammi (breast PET imaging system for breast cancer diagnosis), Sentinella (intraoperative imaging system for surgical guidance), WProbe (portable probe device for accurate, practical imaging applications), and CaremiBrain (neuroimaging application for Alzheimer's disease diagnosis). The company serves surgeons, radiologists, oncologists, and nuclear physicians. Oncovision holds recognition as an innovative SME (PYME INNOVADORA) with validity through May 2027, indicating compliance with Spanish innovation standards. The company has received funding through Generalitat Valenciana's Fondos Plan Resistir Plus and is capitalized by Innvierte, an investment initiative of Spain's CDTI (Centro para el Desarrollo Tecnológico Industrial). The organization emphasizes innovation, commitment, excellence, and continuous improvement in molecular imaging technology for cancer diagnosis and treatment.

Cardea Technology develops BoneStation, an enterprise-class, web-based software solution for DXA-based bone densitometry reporting and workflow management. BoneStation streamlines operations for bone density practices and simplifies the interpretation of bone density scans for reading physicians and radiologists. Originally developed as a custom application for a major teaching hospital, BoneStation has been commercialized and is deployed at hospitals across the United States and Europe. The company specializes in medical software development with expertise in medical imaging integration, DICOM and HL7 standards, and cloud-based application architecture. Cardea leverages modern development technologies including Java, JavaScript, SQL, and cloud platforms (Google Cloud Platform and Amazon Web Services) to deliver responsive, data-driven healthcare applications. The company combines sound software engineering principles with practical, timely software delivery for healthcare clients.

Voiant is a clinical trial imaging Contract Research Organization (CRO) specializing in AI-powered imaging solutions for biopharmaceutical companies. With over 30 years of clinical expertise, Voiant delivers high-quality imaging endpoint data and endpoint adjudication services supporting therapies across oncology, ophthalmology, and respiratory indications from Phase I-IV global trials. The company operates a proprietary, purpose-built AI platform that accelerates imaging processing and analysis while maintaining scientific accuracy through expert human oversight. Voiant's services include independent reading center operations, blinded imaging review (BICR), and specialized imaging biomarker analysis. The company has expanded AI capabilities through acquisition of Voxeleron and maintains a global network of subspecialty-trained clinical readers, regulatory expertise, and over 2,700 registered clinical trial sites. Voiant has contributed to multiple FDA-approved therapies and serves as a trusted partner for sponsors, CROs, and clinical research organizations seeking reliable, reproducible imaging endpoint data and faster turnaround times.

Foresight Imaging is an OEM manufacturer of high-performance video capture boards and PACS connectivity solutions for medical and defense imaging applications. ISO 13485 certified, the company has produced over 100,000 imaging boards in use at elite medical centers worldwide. Foresight Imaging specializes in high-accuracy video streamers and frame grabbers supporting multiple video signal types (HDMI, DVI, SDI, monochrome, RGB, analog, standard and non-standard formats) with sustained transfer rates up to 1.3 GB/second and advanced signal processing (±0.5 ns pixel jitter, 59 dB signal-to-noise ratio, 10-bit A/D conversion). The company's TIMS platform is a 510(k)-accredited analog-to-DICOM workstation solution combining image acquisition software with telemedicine capabilities for remote diagnostics. Applications include surgical recording, angiography, OCT, ultrasound imaging, and specialized medical visualization. Foresight provides comprehensive OEM support including software development kits (C libraries, DirectShow drivers, example programs in .NET, C++, Linux), technical engineering support during development, and automated configuration tools.

Qynapse is a medical software company specializing in AI-powered neuroimaging analysis for central nervous system (CNS) diseases. The company develops advanced algorithms and software platforms that analyze MRI brain scans to provide automated biomarkers, diagnostic support, and disease monitoring capabilities for conditions including Alzheimer's disease, multiple sclerosis, and Parkinson's disease. QyScore® is Qynapse's flagship FDA-cleared (Class II) and CE-marked (Class IIa) software product designed for automatic labeling, visualization, and volumetric quantification of brain structures and lesions from MR images. The software provides volumetric data compared to reference percentile datasets and is intended to support clinicians in CNS disease diagnosis and monitoring. QyPredict® is a research-use-only platform combining genomics, biofluids, neuroimaging, cognitive endpoints, and activity measures to assess CNS disease trajectory. Qynapse addresses a critical clinical need: current CNS disease misdiagnosis rates reach approximately 30%, and the company reports diagnostic accuracy improvement from 66–70% to over 90%. The company serves healthcare providers, pharmaceutical researchers, payers, and patients/caregivers. Products are built on proprietary technology incorporating 20 algorithms and the company's proprietary normative dataset of over 10,000 brain scan images. Regulatory approvals include FDA clearance and CE marking; expansion into additional global markets is underway. The company's clinical advisory board includes leading neurology and radiology experts.